Utility of BRCA1-associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens-Reference-Cited by-同舟云学术

Utility of BRCA1-associated protein 1 immunoperoxidase stain to differentiate benign versus malignant mesothelial proliferations in cytologic specimens

Published:2017-02-16 Issue:4 Volume:45 Page:312-319
ISSN:8755-1039
Container-title:Diagnostic Cytopathology
language:en
Short-container-title:Diagn. Cytopathol.

Author:

McCroskey Zulfia¹^ORCID,Staerkel Gregg¹,Roy-Chowdhuri Sinchita¹

Affiliation:

1. Department of Pathology; Section of Cytopathology, Unit 0053, The University of Texas MD Anderson Cancer Center; Houston Texas

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Reference36 articles.

1. Mesothelioma epidemiology, carcinogenesis, and pathogenesis;Yang;Curr Treat Options Oncol,2008

2. Simian virus 40: The link with human malignant mesothelioma is well established;Carbone;Anticancer Res,2000

3. Pathogenesis of malignant mesothelioma;Carbone;Clin Lung Cancer,2004

4. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group;Husain;Arch Pathol Lab Med,2013

5. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?;Churg;Arch Pathol Lab Med,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update;Archives of Pathology & Laboratory Medicine;2024-02-23

2. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma;Cytopathology;2023-06-19

3. Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology;Cancer Medicine;2022-10-19

4. Optimal diagnosis and treatment of malignant pleual disease: challenging the guidelines;Pleural Disease;2020-03

5. Malignant-Primary (MAL-P) (Mesothelioma);The International System for Serous Fluid Cytopathology;2020